Want to see ECIA full AI Analyst Report?
Top Page
Encision
(OTC:ECIA)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.01
▼(-94.74% Downside)
Action:Downgraded
Date:10/01/26
The score is held down primarily by weak financial performance (declining revenue, widening losses, negative cash flow, and rising leverage). Technicals add additional risk given the strong downtrend versus all major moving averages, while valuation provides limited support due to a loss-driven negative P/E and no dividend yield data.
Positive Factors
Solid Gross Margin
A gross margin near 47% indicates the company continues to retain meaningful value from its products despite declining revenue. This provides an underlying base for improvement if management can align operating expenses with the current revenue scale over the next several quarters.
Negative Factors
Declining Revenue
Several years of shrinking revenue, including another decline of about 8%, indicate weakening commercial scale rather than a temporary fluctuation. Continued contraction can reduce operating leverage, limit investment capacity, and make it harder for the company to absorb fixed costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid Gross Margin
A gross margin near 47% indicates the company continues to retain meaningful value from its products despite declining revenue. This provides an underlying base for improvement if management can align operating expenses with the current revenue scale over the next several quarters.
Read all positive factors
Encision (ECIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$194.12K
Dividend YieldN/A
Average Volume (3M)1.86K
Price to Earnings (P/E)―
Beta (1Y)25.16
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding16,879,644
10 Day Avg. Volume5,294
30 Day Avg. Volume1,864
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.35
Price to Sales (P/S)0.33
P/FCF Ratio-4.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Encision Business Overview & Revenue Model
Company Description
Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The ...
Encision Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
40
Negative
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.74M | 5.78M | 6.56M | 6.59M | 7.35M | 7.67M |
| Gross Profit | 1.29M | 2.71M | 3.51M | 3.14M | 4.03M | 3.79M |
| EBITDA | -177.75K | -542.60K | -95.08K | -544.20K | -217.51K | 55.10K |
| Net Income | -243.57K | -719.08K | -220.20K | -691.78K | -366.00K | 463.34K |
Balance Sheet | ||||||
| Total Assets | 3.51M | 3.70M | 3.67M | 3.81M | 4.13M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 170.76K | 245.11K | 257.43K | 42.51K | 189.00K | 950.00K |
| Total Debt | 1.56M | 1.70M | 1.31M | 1.33M | 1.08M | 1.15M |
| Total Liabilities | 2.05M | 2.27M | 2.02M | 1.98M | 1.64M | 2.05M |
| Stockholders Equity | 1.46M | 1.43M | 1.65M | 1.83M | 2.50M | 2.75M |
Cash Flow | ||||||
| Free Cash Flow | 51.41K | -427.64K | -134.97K | 107.57K | -1.04M | -480.00K |
| Operating Cash Flow | 37.28K | -384.42K | -54.95K | 144.39K | -861.00K | -444.00K |
| Investing Cash Flow | -42.99K | -45.62K | -80.03K | -36.82K | -183.00K | -36.00K |
| Financing Cash Flow | -109.08K | 417.72K | 349.90K | -254.02K | 284.00K | -44.00K |
Encision Technical Analysis
Negative
0.19
Price Trends
0.06
Negative
0.11
Negative
0.14
Negative
Market Momentum
-0.01
Positive
31.71
Neutral
-1.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECIA, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.06, and above the 200-day MA of 0.14, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 31.71 is Neutral, neither overbought nor oversold. The STOCH value of -1.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECIA.
Encision Risk Analysis
Encision disclosed 14 risk factors in its most recent earnings report. Encision reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Encision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $7.93M | -0.69 | -88.90% | ― | 72.50% | 58.34% | |
43 Neutral | $1.67M | >-0.01 | -2135.52% | ― | ― | 99.51% | |
43 Neutral | $7.91M | >-0.01 | -18.55% | ― | ― | ― | |
40 Underperform | $194.12K | -0.66 | -14.67% | ― | ― | ― |
* Healthcare Sector Average
ECIA
Encision
0.01
-0.35
-96.94%
GCTK
GlucoTrack
1.41
-98.19
-98.58%
LUCY
Innovative Eyewear, Inc.
0.92
-1.14
-55.34%
WOK
WORK Medical Technology Group LTD
1.76
-80,998.25
-100.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.